AP NEWS
This content is a press release from our partner BusinessWire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: BusinessWire
This content is a press release from our partner BusinessWire. The AP newsroom and editorial departments were not involved in its creation.

The Worldwide Market for Antihypertensives to 2023 - Patent Expiries Lead to Growth Opportunities for Generic Players - ResearchAndMarkets.com

January 30, 2019

DUBLIN--(BUSINESS WIRE)--Jan 30, 2019--The “Antihypertensives: Global Markets to 2023” report has been added to ResearchAndMarkets.com’s offering.

The current report offers a detailed analysis of the antihypertensive drug market. The study includes a discussion of antihypertensive drugs prescribed for lowering the high blood pressure and for the treatment of pulmonary arterial hypertension (PAH). The market size includes both branded and generic drugs.

The report highlights the current and future market potential of antihypertensive drugs and provides a detailed analysis of the competitive environment, regulatory scenario, patent analysis, pipeline analysis, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2023, as well as market shares for key market players.

The report details market shares of antihypertensive drugs based on drug class and geography. Based on drug class, the market is segmented into ACE inhibitors (angiotensin-converting enzyme inhibitors), ARBs (angiotensin II receptor blockers), beta blockers, calcium channel blockers, diuretics, combination drugs, and others (a segment that includes direct renin inhibitors, alpha blockers, PDE-5 inhibitors, stimulators of soluble guanylate cyclase, endothelin receptor antagonists, vasodilators, and prostacyclin receptors).

Market Dynamics

Drivers

Increasing Prevalence of Hypertension Rising Geriatric Population and Government Assistance for Prescription Drugs Sedentary Lifestyle: Contributing Significantly toward High Risk of Hypertension Improved Awareness of Hypertension: Earlier Diagnosis and Treatment

Restraints

Patent Expirations of Branded Drugs Drug Development Process: High Cost and Pricing Pressures

Opportunities

Patent Expiration: Growth Opportunities for Generic Players Unmet Needs in Low- and Middle-Income Countries

Topics Covered

Chapter 1 Introduction

Chapter 2 Summary & Highlights

Chapter 3 Market & Technology Background

Chapter 4 Market Dynamics

Chapter 5 Market Breakdown by Drug Class

Chapter 6 Market Breakdown by Region

Chapter 7 Regulatory Environment

Chapter 8 Patent Analysis

Chapter 9 Pipeline Analysis

Chapter 10 Competitive Landscape

Chapter 11 Company Profiles

Allergan PLC Arbor Pharmaceuticals LLC Astellas Pharma Inc. Astrazeneca PLC Bayer AG Boehringer Ingelheim GmbH Daiichi Sankyo Co. Ltd. Eli Lilly and Co. Gilead Sciences Inc. Glaxosmithkline PLC Hikma Pharmaceuticals PLC Johnson & Johnson Lupin Ltd. Merck & Co. Inc. Novartis AG Pfizer Inc. Sanofi Takeda Pharmaceutical Co. Ltd. Teva Pharmaceutical Industries Ltd. United Therapeutics Corp.

For more information about this report visit https://www.researchandmarkets.com/research/zqg5x9/the_worldwide?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190130005379/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/30/2019 08:00 AM/DISC: 01/30/2019 08:01 AM

http://www.businesswire.com/news/home/20190130005379/en